Background
Material and methods
Study population
Immunostaining
Microarray analysis
Data analysis and statistics
Results
Study population
n = 179 Characteristics | pFAK-low | pFAK-high | ||
---|---|---|---|---|
Characteristics | n = 113 (%) | n = 66 (%) | p | Adjusted p |
Age [mean +/− SD] | 56.6 [13.2] | 59.5 [11.2] | 0.135 | |
FIGO
|
0.010
| 0.050 | ||
II (n = 7) | 6 (5.3) | 1 (1.5) | ||
III (n = 142) | 95 (84.1) | 47 (71.2) | ||
IV (n = 30) | 12 (6.7) | 18 (27.3) | ||
Grade (1 missing) |
0.002
|
0.014
| ||
Grade 1&2 (n = 49) | 40 (35.7) | 9 (13.6) | ||
Grade 3 (n = 129) | 72 (64.3) | 57 (86.4) | ||
Residual tumor
| 0.229 | |||
no (n = 126) | 76 (67.3) | 50 (75.8) | ||
> 0 cm (n = 53) | 37 (32.7) | 16 (24.2) | ||
Peritoneal carcinomatosis
| 0.126 | |||
no (n = 50) | 36 (31.9) | 14 (21.2) | ||
yes (n = 129) | 77 (68.1) | 52 (78.8) | ||
Ascites
| 0.546 | |||
</= 500 ml (n = 106) | 65 (57.5) | 41 (62.1) | ||
> 500 ml (n = 73) | 48 (42.5) | 25 (37.9) | ||
pNM
|
0.005
|
0.030
| ||
N0 and M0 (n = 20) | 18 (15.9) | 2 (3.0) | ||
N1 and/or M1 (n = 111) | 64 (56.6) | 47 (71.2) | ||
NX or MX* (n = 48) | 31 (27.4) | 17 (25.8) |
n = 179 | FAK-low | FAK-high | ||
---|---|---|---|---|
Characteristics | n = 14 (%) | n = 165 (%) | p | Adjusted p |
Age [mean +/− SD] | 56.1 [18.7] | 57.8 [11.9] | 0.645 | |
FIGO
| 0.150 | |||
II (n = 7) | 1 (7.1) | 6 (3.6) | ||
III (n = 142) | 13 (92.9) | 129 (78.2) | ||
IV (n = 30) | 0 (0) | 30 (18.2) | ||
Grade (1 missing) | 0.535 | |||
Grade 1&2 (n = 49) | 5 (35.7) | 44 (26.8) | ||
Grade 3 (n = 129) | 9 (64.3) | 120 (73.2) | ||
Residual tumor
| 0.082 | |||
no (n = 126) | 7 (50.0) | 119 (72.1) | ||
> 0 cm (n = 53) | 7 (50.0) | 46 (27.9) | ||
Peritoneal carcinomatosis
| 0.539 | |||
no (n = 50) | 5 (35.7) | 45 (27.3) | ||
yes (n = 129) | 9 (64.3) | 120 (72.7) | ||
Ascites
| 0.869 | |||
</= 500 ml (n = 106) | 8 (57.1) | 98 (59.4) | ||
> 500 ml (n = 73) | 6 (42.9) | 67 (40.6) | ||
pNM
|
0.031
| 0.217 | ||
N0 and M0 (n = 20) | 4 (28.5) | 16 (9.8) | ||
N1 and/or M1 (n = 111) | 5 (35.7) | 106 (64.6) | ||
NX or MX* (n = 48) | 5 (35.7) | 42 (25.6) |
Distribution of FAK expression and pFAK abundance in EOC
Correlation of pFAK abundance and FAK expression with clinicopathological parameters
Survival analyses
A. Overall survival | ||||
---|---|---|---|---|
Univariate, n = 172 | Multiple, n = 140 | |||
Characteristics | HR (CI 95%) | p | HR (CI 95%) | p |
Age (per decade)
|
1.48 (1.22-1.79)
|
<0.001
|
1.35 (1.08-1.69)
|
0.010
|
FIGO (IV vs III)
|
2.48 (1.51-4.06)
|
<0.001
|
3.35 (1.84-6.09)
|
<0.001
|
Grade (3 vs 1,2) | 1.56 (0.91-2.68) | 0.105 | 1.64 (0.83-3.24) | 0.155 |
Residual tumor (yes vs no) |
1.77 (1.12-2.78)
|
0.014
| 1.33 (0.78-2.24) | 0.292 |
Peritoneal carcinomatosis (yes vs no)
|
3.11 (1.64-5.90)
|
<0.001
|
3.18 (1.43-7.11)
|
0.005
|
Yoshihara subclassification (subclass 2 vs 1)
|
2.51 (1.49-4.24)*
|
0.001
|
2.23 (1.29-3.87)
|
0.004
|
FAK (high vs low) | 0.85 (0.41-1.77) | 0.671 | 0.91 (0.37-2.24) | 0.830 |
pFAK (high vs low)
| 0.80 (0.50-1.27) | 0.343 |
0.54 (0.31-0.96)
|
0.034
|
B. Progression free survival
| ||||
Univariate, n = 172
|
Multiple, n = 140
| |||
Characteristics
|
HR (CI 95%)
|
p
|
HR (CI 95%)
|
p
|
Age (per decade)
|
1.25 (1.08-1.44)
|
0.003
|
1.19 (1.01-1.41)
|
0.042
|
FIGO (IV vs III)
|
2.81 (1.83-4.31)
|
<0.001
|
3.04 (1.83-5.06)
|
<0.001
|
Grade (3 vs 1,2) | 1.32 (0.89-1.97) | 0.171 | 1.01 (0.61-1.66) | 0.971 |
Residual tumor (yes vs no) |
1.94 (1.35-2.81)
|
<0.001
| 1.40 (0.91-2.17) | 0.127 |
Peritoneal carcinomatosis (yes vs no)
|
2.77 (1.78-4.32)
|
<0.001
|
3.13 (1.80-5.46)
|
<0.001
|
Yoshihara subclassification (subclass 2 vs 1) |
1.61 (1.09-2.36)**
|
0.016
| 1.36 (0.90-2.04) | 0.142 |
FAK (high vs low) | 0.87 (0.48-1.58) | 0.654 | 0.89 (0.41-1.95) | 0.776 |
pFAK (high vs low) | 1.15 (0.81-1.63) | 0.425 | 1.02 (0.66-1.57) | 0.927 |